JBDI vs ACMR

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -15. 5% for JBDI Holdings Limited (JBDI). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (30. 8x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -94. 3% for JBDI Holdings Limited (JBDI). Over 10 years, the gap is even starker: ACMR returned +31. 0% versus JBDI's -93. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JBDI Holdings Limited (JBDI) is the lower-risk stock at 0.

06β versus ACM Research, Inc. 's 3. 17β — meaning ACMR is approximately 5528% more volatile than JBDI relative to the S&P 500. On balance sheet safety, ACM Research, Inc. (ACMR) carries a lower debt/equity ratio of 16% versus 5% for JBDI Holdings Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -15. 5% for JBDI Holdings Limited (JBDI). On earnings-per-share growth, the picture is similar: ACM Research, Inc. grew EPS -10. 5% year-over-year, compared to -221. 4% for JBDI Holdings Limited. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -10. 4% for JBDI Holdings Limited — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -13. 3% for JBDI. At the gross margin level — before operating expenses — JBDI leads at 67. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

JBDI Holdings Limited (JBDI) offers the highest yield at 5. 8%, versus 0. 2% for ACM Research, Inc. (ACMR).

For long-horizon retirement investors, JBDI Holdings Limited (JBDI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 5. 8% yield). ACM Research, Inc. (ACMR) carries a higher beta of 3. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JBDI: -93. 9%, ACMR: +31. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JBDI (Consumer Cyclical) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JBDI is a small-cap income-oriented stock; ACMR is a small-cap high-growth stock. JBDI pays a dividend while ACMR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.